Yahoo Finance

Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

DURHAM, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent ...
Yahoo Finance

Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis

DURHAM, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent ...
Seeking Alpha

Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)

Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function measurements including MP, BCVA ...
The American Journal of Managed Care

Gene Therapy Well Tolerated in Wet AMD, Shows Promise in Visual Acuity

A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD). A single subretinal dose ...
中国日报网

Remote robotic eye surgery achieves breakthrough

Ophthalmologists from the Zhongshan Ophthalmic Center of Sun Yat-sen University reached a milestone on Sunday by successfully conducting the world's first remote robotic subretinal injection surgery.
Mena FN

Atsena Therapeutics Initiates Part B Of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 To Treat X-Linked Retinoschisis

(MENAFN- GlobeNewsWire - Nasdaq) Part B of the LIGHTHOUSE study will enroll adults and children DURHAM, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy ...